| Related Articles |
Hepatocyte Transplantation: Quo Vadis?
Int J Radiat Oncol Biol Phys. 2018 Nov 29;:
Authors: Barahman M, Asp P, Roy-Chowdhury N, Kinkhabwala M, Roy-Chowdhury J, Kabarriti R, Guha C
Abstract
Orthotopic liver transplantation (OLT) has been effective in managing end-stage liver disease since the advent of Cyclosporine immunosuppression therapy in 1980. The major limitations of OLT are organ supply, monetary cost and burden of lifelong immunosuppression. Hepatocyte transplantation (HT), as a substitute for OLT, has been an exciting topic of investigation for several decades. HT is potentially minimally invasive, and can also serve as a vehicle for delivery of personalized medicine through autologous cell transplant after modification ex vivo. However, three major hurdles have prevented large-scale clinical application: (a) availability of transplantable cells; (b) safe and efficient ex vivo gene therapy methods, and (c) engraftment and repopulation efficiency. This review will discuss new sources for transplantable liver cells obtained by lineage-reprogramming, clinically acceptable methods of genetic manipulation, and the development of hepatic irradiation (HIR)-based preparative regimens for enhancing engraftment and repopulation of transplanted hepatocytes. We will also review the results of first three patients with genetic liver disorders who have undergone preparative HIR prior to HT.
PMID: 30503786 [PubMed - as supplied by publisher]
from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2GenWye
No comments:
Post a Comment